Gyors hatású inzulinanalógok és a cukorbetegek pumpakezelése

Translated title of the contribution: Short acting insulin analogues for treating diabetic patients with CSII (continuous subcutaneous insulin infusion)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The use of insulin pump treatment (CSII: continuous subcutaneous insulin infusion) became widely accepted in the last couple of years. A growing body of experiences accumulated in paediatric practice because CSII is preferable for treating young patients with type 1 diabetes. Nevertheless, CSII can be used, if indicated, for treating type 2 diabetic patients as well. Recently, fast acting insulin analogues are exclusively used for CSII. At moment, clinical observations with insulin lispro and insulin aspart are available but experiences with glulisine are still limited. Although some inconsistencies could be observed in the literature, it is widely accepted, that higher reduction in HbA1C values could be achieved by CSII as compared to intensive conservative insulin treatment; this could be more pronounced in cases with high initial HbA1C values. CSII with short acting insulin analogues could lead to a higher reduction of HbA1C values than CSII with human regular insulin. Moreover, the decrease of hypoglycaemic events could be expected in some cases.

Original languageHungarian
Pages (from-to)2223-2226
Number of pages4
JournalOrvosi Hetilap
Volume147
Issue number46
Publication statusPublished - Nov 19 2006

Fingerprint

Short-Acting Insulin
Subcutaneous Infusions
Insulin
Insulin, Regular, Human
Insulin Aspart
Insulin Lispro
Type 1 Diabetes Mellitus
Hypoglycemic Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gyors hatású inzulinanalógok és a cukorbetegek pumpakezelése. / Jermendy, G.

In: Orvosi Hetilap, Vol. 147, No. 46, 19.11.2006, p. 2223-2226.

Research output: Contribution to journalArticle

@article{1e317c11248f44628fe9f86aab71ecee,
title = "Gyors hat{\'a}s{\'u} inzulinanal{\'o}gok {\'e}s a cukorbetegek pumpakezel{\'e}se",
abstract = "The use of insulin pump treatment (CSII: continuous subcutaneous insulin infusion) became widely accepted in the last couple of years. A growing body of experiences accumulated in paediatric practice because CSII is preferable for treating young patients with type 1 diabetes. Nevertheless, CSII can be used, if indicated, for treating type 2 diabetic patients as well. Recently, fast acting insulin analogues are exclusively used for CSII. At moment, clinical observations with insulin lispro and insulin aspart are available but experiences with glulisine are still limited. Although some inconsistencies could be observed in the literature, it is widely accepted, that higher reduction in HbA1C values could be achieved by CSII as compared to intensive conservative insulin treatment; this could be more pronounced in cases with high initial HbA1C values. CSII with short acting insulin analogues could lead to a higher reduction of HbA1C values than CSII with human regular insulin. Moreover, the decrease of hypoglycaemic events could be expected in some cases.",
keywords = "CSII (continuous subcutaneous insulin infusion), Diabetic cotrol, Glulisine, Insulin analogues, Insulin aspart, Insulin lispro",
author = "G. Jermendy",
year = "2006",
month = "11",
day = "19",
language = "Hungarian",
volume = "147",
pages = "2223--2226",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "46",

}

TY - JOUR

T1 - Gyors hatású inzulinanalógok és a cukorbetegek pumpakezelése

AU - Jermendy, G.

PY - 2006/11/19

Y1 - 2006/11/19

N2 - The use of insulin pump treatment (CSII: continuous subcutaneous insulin infusion) became widely accepted in the last couple of years. A growing body of experiences accumulated in paediatric practice because CSII is preferable for treating young patients with type 1 diabetes. Nevertheless, CSII can be used, if indicated, for treating type 2 diabetic patients as well. Recently, fast acting insulin analogues are exclusively used for CSII. At moment, clinical observations with insulin lispro and insulin aspart are available but experiences with glulisine are still limited. Although some inconsistencies could be observed in the literature, it is widely accepted, that higher reduction in HbA1C values could be achieved by CSII as compared to intensive conservative insulin treatment; this could be more pronounced in cases with high initial HbA1C values. CSII with short acting insulin analogues could lead to a higher reduction of HbA1C values than CSII with human regular insulin. Moreover, the decrease of hypoglycaemic events could be expected in some cases.

AB - The use of insulin pump treatment (CSII: continuous subcutaneous insulin infusion) became widely accepted in the last couple of years. A growing body of experiences accumulated in paediatric practice because CSII is preferable for treating young patients with type 1 diabetes. Nevertheless, CSII can be used, if indicated, for treating type 2 diabetic patients as well. Recently, fast acting insulin analogues are exclusively used for CSII. At moment, clinical observations with insulin lispro and insulin aspart are available but experiences with glulisine are still limited. Although some inconsistencies could be observed in the literature, it is widely accepted, that higher reduction in HbA1C values could be achieved by CSII as compared to intensive conservative insulin treatment; this could be more pronounced in cases with high initial HbA1C values. CSII with short acting insulin analogues could lead to a higher reduction of HbA1C values than CSII with human regular insulin. Moreover, the decrease of hypoglycaemic events could be expected in some cases.

KW - CSII (continuous subcutaneous insulin infusion)

KW - Diabetic cotrol

KW - Glulisine

KW - Insulin analogues

KW - Insulin aspart

KW - Insulin lispro

UR - http://www.scopus.com/inward/record.url?scp=34249658359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249658359&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 2223

EP - 2226

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 46

ER -